United Therapeutics (UTHR) reported its Q3 2019 earnings on October 30, 2019. The company reported a profit of $163 million or $3.83 per share. Revenues were an impressive $402 million with net income of $132 million. While the year-over-year comparisons were slightly down, the numbers delivered are considered good when one considers that generic versions of some United Therapeutics drugs are now on the market.
By The Numbers
- Net product sales of Remodulin were $168.3m vs. $153.6m a year ago.
- Net product sales of Tyvaso were $110.8m vs. $107.8m a year ago
- Net